IL17A and metabolic dysfunction-associated steatohepatitis: IL-17A signaling triggers proinflammatory, fibrogenic, and tumorigenic responses in myeloid cells, which, in turn, induce metabolic alterations in hepatocytes affected by nonalcoholic steatohepatitis (NASH) and ALD.